Sinphar Pharmaceutical Co Ltd
TWSE:1734
Sinphar Pharmaceutical Co Ltd
TWSE:1734
Price:
30.75
TWD
1.49%
Market Closed
Market Cap:
NT$5.8B
Income Statement
Earnings Waterfall
Sinphar Pharmaceutical Co Ltd
Sinphar Pharmaceutical Co Ltd
Income Statement
Sinphar Pharmaceutical Co Ltd
Sinphar Pharmaceutical Co Ltd
Currency: TWD
| Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||
| Interest Expense |
24
|
25
|
26
|
28
|
30
|
32
|
33
|
34
|
34
|
35
|
36
|
37
|
37
|
36
|
36
|
|
| Revenue |
2 485
N/A
|
2 593
+4%
|
2 735
+5%
|
2 857
+4%
|
2 959
+4%
|
2 970
+0%
|
2 977
+0%
|
2 963
0%
|
2 969
+0%
|
3 011
+1%
|
3 045
+1%
|
3 151
+3%
|
3 179
+1%
|
3 222
+1%
|
3 346
+4%
|
|
| Gross Profit | ||||||||||||||||
| Cost of Revenue |
(1 543)
|
(1 593)
|
(1 679)
|
(1 765)
|
(1 840)
|
(1 893)
|
(1 895)
|
(1 872)
|
(1 847)
|
(1 836)
|
(1 872)
|
(1 914)
|
(1 915)
|
(1 911)
|
(1 924)
|
|
| Gross Profit |
942
N/A
|
1 000
+6%
|
1 057
+6%
|
1 091
+3%
|
1 119
+2%
|
1 078
-4%
|
1 082
+0%
|
1 091
+1%
|
1 123
+3%
|
1 175
+5%
|
1 173
0%
|
1 237
+6%
|
1 264
+2%
|
1 312
+4%
|
1 422
+8%
|
|
| Operating Income | ||||||||||||||||
| Operating Expenses |
(1 050)
|
(1 023)
|
(853)
|
(894)
|
(895)
|
(912)
|
(928)
|
(805)
|
(851)
|
(855)
|
(854)
|
(943)
|
(933)
|
(959)
|
(1 015)
|
|
| Selling, General & Administrative |
(571)
|
(583)
|
(599)
|
(622)
|
(635)
|
(658)
|
(668)
|
(673)
|
(707)
|
(724)
|
(742)
|
(792)
|
(792)
|
(817)
|
(868)
|
|
| Research & Development |
(479)
|
(440)
|
(254)
|
(272)
|
(260)
|
(254)
|
(260)
|
(133)
|
(143)
|
(131)
|
(112)
|
(151)
|
(141)
|
(142)
|
(147)
|
|
| Operating Income |
(108)
N/A
|
(23)
+79%
|
204
N/A
|
197
-3%
|
224
+13%
|
166
-26%
|
154
-7%
|
286
+85%
|
272
-5%
|
320
+18%
|
319
0%
|
294
-8%
|
332
+13%
|
354
+7%
|
408
+15%
|
|
| Pre-Tax Income | ||||||||||||||||
| Interest Income Expense |
(26)
|
(6)
|
2
|
(1)
|
(7)
|
(15)
|
(21)
|
(18)
|
(8)
|
(9)
|
(17)
|
(7)
|
(11)
|
(36)
|
(29)
|
|
| Gain/Loss on Disposition of Assets |
(2)
|
(2)
|
(2)
|
0
|
1
|
6
|
6
|
8
|
7
|
0
|
0
|
1
|
0
|
3
|
2
|
|
| Total Other Income |
27
|
29
|
36
|
48
|
55
|
51
|
46
|
29
|
20
|
20
|
11
|
19
|
17
|
20
|
19
|
|
| Pre-Tax Income |
(109)
N/A
|
(2)
+99%
|
240
N/A
|
245
+2%
|
273
+11%
|
208
-24%
|
186
-11%
|
306
+64%
|
291
-5%
|
332
+14%
|
314
-5%
|
307
-2%
|
338
+10%
|
341
+1%
|
400
+17%
|
|
| Net Income | ||||||||||||||||
| Tax Provision |
(31)
|
(34)
|
(99)
|
(81)
|
(83)
|
(2)
|
28
|
51
|
100
|
22
|
15
|
(22)
|
(48)
|
(46)
|
(64)
|
|
| Income from Continuing Operations |
(140)
|
(35)
|
141
|
164
|
190
|
206
|
214
|
357
|
391
|
353
|
329
|
285
|
290
|
295
|
334
|
|
| Income to Minority Interest |
155
|
132
|
57
|
60
|
57
|
62
|
63
|
18
|
14
|
8
|
4
|
19
|
17
|
16
|
11
|
|
| Net Income (Common) |
15
N/A
|
97
+549%
|
198
+105%
|
225
+13%
|
247
+10%
|
269
+9%
|
277
+3%
|
375
+36%
|
405
+8%
|
361
-11%
|
333
-8%
|
305
-9%
|
307
+1%
|
310
+1%
|
346
+11%
|
|
| EPS (Diluted) |
0.09
N/A
|
0.5
+456%
|
1.04
+108%
|
1.18
+13%
|
1.29
+9%
|
1.41
+9%
|
1.45
+3%
|
1.97
+36%
|
2.13
+8%
|
1.89
-11%
|
1.74
-8%
|
1.6
-8%
|
1.63
+2%
|
1.63
N/A
|
1.82
+12%
|
|
Switch to:
Switch to:
See Also
Discover More
